News and articles

Drug shortages have become a more common occurrence across the healthcare sector, negatively impacting the care delivered to patients and increasing stress amongst healthcare professionals. Shortages are influenced by many factors, from global events (e.g. COVID-19, Russia-Ukraine war) to financial and economical, increasing the cost of the drug and limiting the manufacture (e.g. cost of raw materials and energy to produce the drugs) (1). As a result, drug supply issues are often sudden and require immediate alternatives to be made available. This article aims to provide users with some helpful suggestions for how to manage a drug shortage within iQemo. (1) The Pharmaceutical Journal, PJ, June 2023, Vol 310, No 7974; 310(7974): :DOI:10.1211/ PJ.2023.1.189330

We are very pleased to report the next successful iQemo activation within SA Health at Lyell McEwin Hospital, Adelaide, South Australia

iQHealthTech in collaboration with Altera Digital Health in Australia have celebrated the successful go-live of iQemo at Mount Gambier and Districts Health Service!

Biosimilar switching is becoming more common as Rituximab, Trastuzumab and Bevacizumab all have biosimilars on the market. Due to stock shortages and contract prices, there may be a need to switch biosimilars more regularly. This will become more common as additional biosimilar products come to the market. iQemo can facilitate biosimilar switching through several mechanisms.

iQ HealthTech upgrade their service desk for improved, email, phone, and technical support.

Beyond the standard benefits of e-prescribing, iQemo provides many additional features that will help your organisation further improve the safety of its patients receiving chemotherapy.

An explanation of the iQemo settings hierarchy, from drug-formulary to drug-level, and how that relates to dose capping.